Incyte reports first data for JAK-1 inhibitor INCB39110

Incyte Corp. (NASDAQ:INCY) presented Phase II data on Thursday at the European Academy of Dermatology and Venereology meeting from a double-blind, dose-escalation trial evaluating INCB39110, a Janus kinase-1 (JAK-1) inhibitor, to treat chronic plaque psoriasis. Oral INCB39110 reduced mean static Physician Global Assessment (sPGA) scores from baseline to day 28, the primary endpoint, by 22.2% at the once-daily 100 mg dose (n=9), 29.4% at the once-daily 200 mg dose (n=9), 35.2% at the twice-daily 200 mg dose (n=9) and 42.4% at the once-daily 600 mg dose (n=11) vs. 12.5% for placebo (n=12) (p<0.05 for the once-daily 600 mg dose vs. placebo).

Additionally, the proportion of patients receiving INCB39110 who achieved a PASI 50 response at day 28, a secondary endpoint, was 22.2% at the once-daily 100 mg dose, 66.7% at the once-daily 200 mg dose, 44.4% at the twice-daily 200 mg dose and 81.8% at the once-daily 600 mg dose vs. 8.3% for placebo (p<0.05 for the once-daily 200 and 600 mg doses vs. placebo). ...